top of page

Swati Gupta;  Donald Grant, Robert Garry, Abdulwasiu Bolagi Tiamiyu, Sandhya Vasan, Stephen Kennedy, Bernice Dahn, James Duworko, Rebecca Grais, Marija Zaric, Patricia Fast; Gaudensia Mutua, Devin Hunt, Kathleen Walker, Shaun Palmer,  Bridgette Connell, Jennifer Lehrman;  LEAP4WA Consortium. Lassa Fever Vaccine Efficacy and Prevention For West Africa (LEAP4WA). 11th EDCTP Forum. November 2023. 

An IAVI-led consortium is advancing a Lassa vaccine candidate based on the recombinant vesicular stomatitis virus (rVSV) platform technology. LEAP4WA will conduct a Phase IIb efficacy trial, evaluating the efficacy of VSV∆G-LASV-GPC for the prevention of laboratory confirmed, symptomatic Lassa fever in a West African LASV-NP seronegative population.
LEAP4WA will also develop state-of-the-art clinical research capacity in West Africa that can be utilized for other Emerging Infectious Diseases in the future.

 

PUBLICATIONS

Swati Gupta; Patricia Fast; Jennifer Lehrman; Matt Price; LEAP4WA Consortium. Lassa Fever Vaccine Efficacy and Prevention For West Africa (LEAP4WA). 10th EDCTP Forum. October 2021. 

An IAVI-led consortium is advancing a Lassa vaccine candidate based on the recombinant vesicular stomatitis virus (rVSV) platform technology. The vaccine candidate demonstrated 100% efficacy against LASV in a nonhuman primate challenge study. Furthermore, it uses the same technology as Merck’s ERVEBO® vaccine, which has been shown to be safe and efficacious in preventing Ebola virus disease and is licensed in multiple countries.

bottom of page